Cellares announced that Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners, has made a $50 million growth equity investment in the company’s Series D financing, bringing the total round to $327 million.
Prime Radiant adds to a distinguished list of investors that joined the Series D financing round back in January, including ARK Invest, investment funds managed by BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., Duquesne Family Office, Baillie Gifford, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors.
The investment supports the next phase of Cellares’ global smart factory buildout. Cellares’ European manufacturing facility, under construction in Leiden, the Netherlands, is designed to serve drug sponsors across global markets with the same automated manufacturing infrastructure available in the U.S. and will be GMP-ready in 2027.
Prime Radiant’s experience in European healthcare services, anchored by offices in Milan and Munich, positions it to support Cellares’ expansion as demand for automated cell therapy manufacturing grows across the region.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!